EXOZYMES INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
EXOZYMES INC. (EXOZ) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $961.07 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- EXOZYMES INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $961.07K.
- EXOZYMES INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $501.10K, a 57.94% increase year-over-year.
- EXOZYMES INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $317.28K, a 122.17% increase year-over-year.
- EXOZYMES INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-09-30 was $317.28K, a 417.05% increase year-over-year.
- EXOZYMES INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $1.65M, a 46.50% increase from fiscal 2024.
- EXOZYMES INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $1.13M, a 299.82% increase from fiscal 2023.
- EXOZYMES INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $281.54K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $961.07K 10-Q · filed 2026-08-13 | $1.46M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $501.10K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $1.65M 10-K · filed 2026-03-30 | |||
| 2025-03-31 | $317.28K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $1.13M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $317.28K 10-Q · filed 2024-11-12 | $665.55K derived: sum of 2 quarters · filed 2024-11-12 | $808.36K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2024-06-30 | $348.27K 10-Q · filed 2024-11-12 | $491.08K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2024-03-31 | $142.81K 10-Q · filed 2024-11-12 | |||
| 2023-12-31 | $281.54K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $61.36K 10-Q · filed 2024-11-12 | $120.31K derived: sum of 2 quarters · filed 2024-11-12 | $174.43K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $58.95K 10-Q · filed 2024-11-12 | $113.07K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $54.13K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |